Clomiphene Citrate in Infertile Men With Idiopathic Oligoasthenozoospermia

The Effect of Clomiphene Citrate on Sperm Parameters in Infertile Men With Idiopathic Oligoasthenozoospermia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06564961

Enrollment

Registered

2024-08-21

Start date

2022-07-01

Completion date

2023-12-31

Last updated

2024-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Male

Keywords

Male infertility, Oligoasthenozoospermia, Testosterone, Clomiphene citrate

Brief summary

The goal of this clinical trial is to learn if drug clomiphene citrate improves sperm parameters in infertile men with idiopathic oligoasthenozoospermia. It will also learn about the safety of clomiphene citrate. The main questions it aims to answer are: * Does drug clomiphene citrate change sperm count and motility in infertile men with idiopathic oligoasthenozoospermia? * What medical problems do participants have when taking drug clomiphene citrate? Researchers will compare drug clomiphene citrate to a placebo (a look-alike substance that contains no drug) to see if drug clomiphene citrate works to treat idiopathic oligoasthenozoospermia.

Interventions

DRUGClomiphene Citrate

50 mg tab once daily

DRUGPlacebo

1 tab once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

Placebo

Eligibility

Sex/Gender

MALE

Age

25 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Infertile men * Idiopathic oligoasthenozoospermia (serum FSH and serum LH range was 2-7 IU/mL and serum testosterone level was \>300 ng/dl)

Exclusion criteria

* Azoospermia * Body mass index \<18 kg/m2 and \>30 kg/m2 * Any abnormality on genital examination and scrotal sonogram * History of genital diseases & genital surgery * Medical and endocrine disorders like uncontrolled diabetes mellitus, severe kidney disease and liver insufficiency * Psycho-sexual abnormalities * Antioxidant supplements in previous 3 months * Smoking, drug, alcohol or substance abuse * History of chemotherapy or radiotherapy * Presence of any gross female factor abnormality

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in sperm motility at 12 weeks	Baseline and 12 weeks	Sperm motility was percentage of progressive & non-progressive motility
Change from baseline in sperm count at 12 weeks	Baseline and 12 weeks	Sperm count was in million per milliliter of semen

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026